• Outlook Therapeutics received FDA approval for its wet age-related macular degeneration (wet AMD) drug, LYTENAVA, on July 27, 2026.
  • The stock experienced an initial rally leading up to and on the news of the approval.
  • However, profit-taking began on July 27, with the stock closing down 24.20%, and continues today with a further 16% decline as investors lock in gains.